Latest Manufacturing Strategy News

Archer Materials is progressing toward demonstrating a working qubit this year while scaling quantum device fabrication from lab prototypes to wafer-scale manufacturing using semiconductor industry standards.

Pure Resources has partnered with Oak Ridge National Laboratory to develop a rare earth extraction process from its Garnet Hills garnet, aiming to add critical minerals value alongside its industrial minerals business.

Alterity Therapeutics has secured FDA alignment on the chemistry and manufacturing controls for its ATH434 Phase 3 trial in Multiple System Atrophy, marking a pivotal regulatory milestone ahead of the planned mid-2026 End-of-Phase 2 meeting.

Wide Open Agriculture appoints Craig Swan as CEO and pivots to a contract manufacturing model to improve economics and scale lupin protein production, while receiving a A$1.69 million R&D tax rebate.

Archer Materials has progressed its Biochip program by completing the alpha prototype and Stage 1 project with IMEC, now advancing to develop a beta prototype suitable for external use and clinical validation.

Clarity Pharmaceuticals has signed a significant manufacturing supply agreement with Theragenics to produce copper-64, a key isotope for its upcoming prostate cancer diagnostic, Cu-SAR-bisPSMA. This deal strengthens Clarity’s US supply network ahead of anticipated FDA approval and commercial launch.

Peak Processing Limited has renewed and expanded its manufacturing agreement with Electric Brands, securing an expected annual production of approximately 1.4 million Sweet Justice cannabis beverage units. This deal reinforces Peak’s position in North America’s regulated cannabis beverage market and supports growth in Canada and the US.

SDI Limited reported a modest 2% dip in net profit for H1 FY26 despite a 2.7% rise in sales, driven by growth in aesthetics and exports. The company faces challenges from regulatory bans on Amalgam products while advancing plans for manufacturing upgrades and a potential acquisition.

Titomic Limited reports a significant drop in revenue and increased losses for the six months ending December 2025, alongside a strategic financial year change to align with global subsidiaries.

AdAlta Limited reported a $2.44 million loss for H1 FY26 while progressing a key CAR-T therapy collaboration and raising $2.8 million in capital. The company’s ‘East to West’ immunotherapy strategy gains momentum with regulatory tailwinds and cost efficiencies.

Breville Group Limited has reported a record half-year revenue of $1.1 billion, driven by strong coffee sales and new market growth, while successfully managing US tariff impacts to maintain flat EBIT year-on-year.

Breville Group Limited has reported a record half-year revenue of AUD 1.1 billion, overcoming US tariff challenges through strategic manufacturing shifts and robust product innovation. The company’s steady profitability and geographic expansion signal a confident growth trajectory.